RxDoctor Payments Data

Satya Garimella, MD

Clinical Cardiac Electrophysiology · Jeffersonville, INNPI 1164452850

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Boston Scientific at 34.7% of the total. Reporting peaked in 2023 at $5,210 and has fallen 67.8% since, to $1,676 in 2025.

$19,586in general payments, 2019–2025

Across 278 payments — averaging $70.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$7K
  • Abbott$4K
  • Medtronic$2K
  • Medical Device Business Services, Inc.$2K
  • Biosense Webster, Inc.$792
  • Inari Medical, Inc.$642
  • plus $4K from 28 others
$37,285in research payments, 2019–2025

Across 11 payments — averaging $3389.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Elutia, Inc.$37K

What the payments were for

  • Travel & lodging$8,04941%
  • Food & beverage$11,50359%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,586 in reported general payments places this provider in the 55th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$377,356
Medicare patients
1,054
Services billed
5,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban539$530,551
XareltoRivaroxaban168$177,052
MultaqDronedarone Hcl40$58,149
EntrestoSacubitril/Valsartan34$55,007
FarxigaDapagliflozin Propanediol30$32,636
Dofetilide161$28,606
Metoprolol Succinate572$6,101
Amiodarone Hcl106$4,866
Diltiazem 24hr Er (Cd)Diltiazem Hcl150$3,540
Flecainide Acetate43$3,441
Midodrine Hcl38$3,256
Spironolactone321$2,411
Ranolazine ErRanolazine21$2,184
Mexiletine Hcl18$2,109
ClopidogrelClopidogrel Bisulfate192$2,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$530,551539 claims
Johnson & JohnsonXarelto$70$177,052168 claims
Sanofi-aventis U.S. LLCMultaq$228$58,14940 claims
NovartisEntresto$106$55,00734 claims
AstraZenecaFarxiga$274$32,63630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →